在IBS类症状的差异诊断中,还有很多悬而未决的结局
Greger Lindberg1,2, Ghazaleh Mohammadian1,2
1Department of Medicine at Huddinge, Karolinska Institutet, Stockholm, Sweden.
Frontiers in medicine
|July 24, 2023
概括
许多曾经被诊断为刺激性肠综合征 (IBS) 的疾病现在可以治疗. 然而,一些患者仍然会出现类似于IBS的症状,可能与结缔组织或自闭症谱系障碍有关.
科学领域:
- 胃肠病学 胃肠病学
- 神经胃肠病学 神经胃肠病学
- 遗传学 遗传学 是一个
背景情况:
- 自20世纪70年代以来,刺激性肠综合征 (IBS) 诊断发生了显著的进化.
- 进步已经确定了以前被误诊为IBS的可治疗疾病,包括乳病和炎症性肠病.
- 很大一部分患者仍然存在不明原因的IBS类症状.
研究的目的:
- 重新评估患有IBS类症状的患者的诊断环境.
- 为了确定患有持续性,无法解释的胃肠道疾病的患者潜在的潜在疾病.
- 提出修订后的临床方法,重点关注特定的患者子组.
主要方法:
- 对IBS的历史和当前诊断标准的审查.
- 分析胃肠道疾病诊断能力的发展.
- 临床观察和未解释IBS类症状的患者的建议分类.
主要成果:
- 之前被诊断为IBS的三分之二的患者现在可以接受特定的诊断 (例如,胆酸腹,腹病).
- 建议有两个主要的群体具有无法解释的IBS类症状:具有结缔组织疾病 (例如,埃勒斯-丹洛斯综合征) 和患有自闭症谱系障碍的人.
- 结缔组织障碍可能涉及肠道运动和透性问题;自闭症谱系障碍存在影响肠道感知的感知和焦虑相关挑战.
结论:
- 持续的IBS类症状需要考虑结合组织疾病和自闭症谱系障碍.
- 早期识别自闭症谱系障碍对于管理胃肠道和肠外症状至关重要.
- 进一步的研究可能会在特定的患者亚组中发现IBS类症状的其他可治疗机制.
相关概念视频
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
194
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
194
Irritable Bowel Syndrome I: Introduction
321
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
321
Drugs for Treatment of Diarrhea-Predominant IBS
216
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
216
Irritable Bowel Syndrome III: Medical and Nursing Management
244
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
244
Chronic Bowel Disorders: Introduction
489
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
489
Drugs for Treatment of Constipation-Predominant IBS
218
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
218


